Cargando…
Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis
BACKGROUND: Lymphatic filariasis (LF) is a neglected tropical disease, and the Global Program to Eliminate LF delivers mass drug administration (MDA) to 500 million people every year. Adverse events (AEs) are common after LF treatment. METHODOLOGY/PRINCIPAL FINDINGS: To better understand the pathoge...
Autores principales: | Andersen, Britt J., Rosa, Bruce A., Kupritz, Jonah, Meite, Aboulaye, Serge, Traye, Hertz, Marla I., Curtis, Kurt, King, Christopher L., Mitreva, Makedonka, Fischer, Peter U., Weil, Gary J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762072/ https://www.ncbi.nlm.nih.gov/pubmed/31557154 http://dx.doi.org/10.1371/journal.pntd.0007697 |
Ejemplares similares
-
Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis
por: Andersen, Britt J, et al.
Publicado: (2018) -
Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
por: Bjerum, Catherine M, et al.
Publicado: (2019) -
Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d’Ivoire
por: Loukouri, Agodio, et al.
Publicado: (2020) -
Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
por: Budge, Philip J., et al.
Publicado: (2018) -
Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa
por: Stolk, Wilma A., et al.
Publicado: (2022)